AivoCode

Executive Summary

AivoCode is an AI-driven drug discovery company based in San Francisco, founded in 2020, with a focus on neuroprotection. The company leverages machine learning to identify and develop therapeutics that mitigate secondary brain injury following trauma, stroke, or oxygen deprivation. By targeting the underlying processes of secondary injury, which unfolds over hours to days, AivoCode aims to reduce preventable damage and improve patient outcomes. While still in a private stage with limited public information, the company's approach aligns with a growing trend in AI-powered biotechnology, offering potential for innovative treatments in neurology.

Upcoming Catalysts (preview)

• TBDSeries A Funding Announcement60% success
• TBDPreclinical Data Release for Lead Candidate55% success
• TBDStrategic Partnership with Major Pharma40% success